Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Authors not listed
Regeneron Pharmaceuticals · 2014
Abstract
The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2014). Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD. <em>Regeneron Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT02061865
Vancouver
Anonymous. Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD. Regeneron Pharmaceuticals. 2014.
BibTeX
@misc{anon2014PhaseS,
title = {Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD},
author = {Anonymous},
journal = {Regeneron Pharmaceuticals},
year = {2014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Apellis Pharmaceuticals, Inc. 2015
Open access · US-GOV
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)
Regeneron Pharmaceuticals 2015
Open access · US-GOV
A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 2013
Open access · US-GOV
A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration
Kodiak Sciences Inc 2021
Open access · US-GOV
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
OcuTerra Therapeutics, Inc. 2016
Open access · US-GOV
A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
EyebioKorea, Inc. 2024
Open access · US-GOV